Literature DB >> 31203726

Renal Denervation in Isolated Systolic Hypertension Using Different Catheter Techniques and Technologies.

Karl Fengler1, Karl-Philipp Rommel1, Razvan Lapusca1, Stephan Blazek1, Christian Besler1, Philipp Hartung1, Maximilian von Roeder1, Karl-Patrik Kresoja1, Steffen Desch1, Holger Thiele1, Philipp Lurz1.   

Abstract

Patients with isolated systolic hypertension (ISH) are thought to show a diminished blood pressure (BP)-lowering effect after renal sympathetic denervation (RDN). This conclusion is mostly derived from unipolar radiofrequency catheter ablation studies. Limited data for newer RDN technologies exist. We used data from the RADIOSOUND-HTN (Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension) comparing 3 different RDN approaches to investigate a possible interaction between ISH and RDN response. One hundred twenty patients were stratified by having ISH or combined systolic-diastolic hypertension (CH). Of these, 39 underwent radiofrequency ablation of the renal main arteries, 39 combined radiofrequency ablation of the main and branch arteries, and 42 were treated with ultrasound-based ablation of the main renal artery. Patients with ISH (n=61) were older and had lower systolic and diastolic BP on ambulatory measurement (ambulatory BP measurement) at baseline in comparison to CH (n=59). At 3 months, patients with ISH showed a less pronounced BP-lowering effect of RDN as compared to patients with CH (daytime average -5.9±11.8 versus -13.3±11.7 mm Hg, P=0.001). This difference was significant for radiofrequency ablation of the renal main arteries and ultrasound-based ablation of the main renal artery treatment but did not reach significance in the radiofrequency ablation of the main and branch arteries group. After adjustment for baseline BP values and age, there was no significant difference in BP reduction between ISH and CH. Using unadjusted BP values, RDN seems to be more effective in CH than in ISH. However, adjusting for baseline BP values revealed similar BP reduction in ISH and CH patients, irrespective of the RDN treatment used. The value of ISH as predictor for successful RDN might have been overestimated in the past. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT02920034.

Entities:  

Keywords:  blood pressure; catheter ablation; denervation; hypertension; renal artery

Mesh:

Substances:

Year:  2019        PMID: 31203726     DOI: 10.1161/HYPERTENSIONAHA.119.13019

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  3 in total

1.  Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system.

Authors:  Manuel Wallbach; Ellen Born; Deborah Kämpfer; Stephan Lüders; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  Clin Res Cardiol       Date:  2019-08-06       Impact factor: 5.460

Review 2.  Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.

Authors:  David E Kandzari; Felix Mahfoud; Michael A Weber; Raymond Townsend; Gianfranco Parati; Naomi D L Fisher; Melvin D Lobo; Michael Bloch; Michael Böhm; Andrew S P Sharp; Roland E Schmieder; Michel Azizi; Markus P Schlaich; Vasilios Papademetriou; Ajay J Kirtane; Joost Daemen; Atul Pathak; Christian Ukena; Philipp Lurz; Guido Grassi; Martin Myers; Aloke V Finn; Marie-Claude Morice; Roxana Mehran; Peter Jüni; Gregg W Stone; Mitchell W Krucoff; Paul K Whelton; Konstantinos Tsioufis; Donald E Cutlip; Ernest Spitzer
Journal:  Circulation       Date:  2022-03-14       Impact factor: 29.690

3.  Effect of Renal Denervation for the Management of Heart Rate in Patients With Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Le Li; Yulong Xiong; Zhao Hu; Yan Yao
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.